HCA Healthcare, Inc. (HCA)

Achilles Therapeutics Stock Forecast

Stock Price Forecast

The 13 analysts that cover Achilles Therapeutics stock have a consensus rating of "Buy" and an average price target of $395.54, which forecasts a 8.03% increase in the stock price over the next year. The lowest target is $336 and the highest is $440.

Price Target: $395.54 (+8.03%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$336	$395.54	$400	$440
Change	-8.23%	+8.03%	+9.24%	+20.17%

Analyst Ratings

The average analyst rating for Achilles Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	4	4	4	4	2	2
Buy	7	6	6	6	6	6
Hold	4	6	7	6	8	8
Sell	1	1	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	17	17	16	16	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Benjamin Rossi JP Morgan	JP Morgan	Hold Maintains $360 → $370	Hold	Maintains	$360 → $370	+1.05%	Aug 4, 2025
Andrew Mok Barclays	Barclays	Buy Maintains $416 → $390	Buy	Maintains	$416 → $390	+6.51%	Jul 28, 2025
Ben Hendrix RBC Capital	RBC Capital	Buy Maintains $404 → $401	Buy	Maintains	$404 → $401	+9.52%	Jul 28, 2025
Craig Hettenbach Morgan Stanley	Morgan Stanley	Hold Maintains $410 → $400	Hold	Maintains	$410 → $400	+9.24%	Jul 28, 2025
Justin Lake Wolfe Research	Wolfe Research	Buy → Hold Downgrades n/a	Buy → Hold	Downgrades	n/a	n/a	Jul 28, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

75.69B

Increased by 7.20%

from 70.60B

Revenue Next Year

79.19B

Increased by 4.63%

from 75.69B

EPS This Year

25.61

Increased by 16.41%

from 22.00

EPS Next Year

28.43

Increased by 11.00%

from 25.61

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	51.53B	58.75B	60.23B	64.97B	70.60B	75.69B	79.19B	83.48B
Revenue Growth	0.38%	14.01%	2.52%	7.86%	8.67%	7.20%	4.63%	5.42%
EPS	10.93	21.16	19.15	18.97	22.00	25.61	28.43	32.17
EPS Growth	8.54%	93.60%	-9.50%	-0.94%	15.97%	16.41%	11.00%	13.16%
Forward PE	-	-	-	-	-	14.30	12.88	11.38
No. Analysts	-	-	-	-	-	27	27	16

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	79.6B	84.8B	90.1B
Avg	75.7B	79.2B	83.5B
Low	72.8B	74.9B	79.0B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	12.7%	12.1%	13.8%
Avg	7.2%	4.6%	5.4%
Low	3.0%	-1.1%	-0.3%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	27.17	31.52	35.82
Avg	25.61	28.43	32.17
Low	24.16	26.50	30.44

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	23.5%	23.1%	26.0%
Avg	16.4%	11.0%	13.2%
Low	9.8%	3.5%	7.1%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.